Literature DB >> 19758400

Intraocular pressure change after temporal clear corneal phacoemulsification in normal eyes.

Inci Irak-Dersu1, Chris Nilson, Norm Zabriskie, Jane Durcan, Horace J Spencer, Alan Crandall.   

Abstract

PURPOSE: To evaluate short- and long-term intraocular pressure (IOP) changes after temporal clear corneal phacoemulsification in normal eyes.
METHODS: The charts of 266 consecutive non-glaucoma patients who underwent uneventful cataract surgery were reviewed. We recorded preoperative and postoperative (1 day, 1 week, 1 month, 3 months, 6 months, 1 year and 2 years) IOP measurements as well as anatomical properties obtained using Zeiss Humphrey IOL Master (Zeiss Meditech, Dublin, California, USA).
RESULTS: Mean IOP reduction after cataract surgery was 8.2%, 4.6%, 6.7% and 7.8% at 3 months, 6 months, 1 year and 2 years, respectively. Lens thickness was the only anatomical characteristic that correlated significantly with IOP decrease after surgery.
CONCLUSION: Temporal clear corneal phacoemulsification results in a decrease in postoperative IOP that persists for 2 years following surgery.

Entities:  

Mesh:

Year:  2009        PMID: 19758400     DOI: 10.1111/j.1755-3768.2009.01569.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  3 in total

1.  Comparison of brimonidine-timolol and dorzolamide-timolol in the management of intraocular pressure increase after phacoemulsification.

Authors:  Adem Turk; Osman Melih Ceylan; Gokcen Gokce; Mehmet Borazan; Mehmet Kola
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

2.  Early changes in intraocular pressure following phacoemulsification.

Authors:  Mitra Zamani; Mostafa Feghhi; Afsaneh Azarkish
Journal:  J Ophthalmic Vis Res       Date:  2013-01

3.  Effect of Phacoemulsification on Intraocular Pressure in Healthy Subjects and Glaucoma Patients.

Authors:  Sung Uk Baek; Soonil Kwon; In Won Park; Wool Suh
Journal:  J Korean Med Sci       Date:  2019-01-30       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.